NAVANAPHAR Navana Pharmaceuticals Limited
Pharmaceuticals & Chemicals
Tk 63.4 as of 2026-11-12 14:00:00
Rank 22 of all scored
Data completeness 100%
Data completeness 100%
Score breakdown
Consistency 95
Profitability 64
Solvency 100
Valuation 83
Weights: consistency 30%, profitability 30%, solvency 20%, valuation 20%; then risk flags add or subtract points. Full method
Why this score
Strengths
- Consistency EPS grew in 4 of 4 years
- Profitability Net profit growing 24.61% a year
- Solvency Practically debt-free (loan risk cannot hurt it)
- Valuation P/E 10.69 is low (general benchmark ≤ 12)
- Valuation Trades near book value (P/NAV 1.28x)
Concerns
- Profitability Average ROE only 8.84% (below 10%: capital not working hard)
Risk flags
- Mid cap (Tk 200-1,000 cr)
Valuation
P/E
P/E audited
P/E current
P/B
NAV per share
EPS (last audited year)
Graham fair value
Margin of safety
52-week range
39.3% above the low, 18.7% below the high. Near the low is only interesting if profit is intact (see concerns above) and the fall has a temporary cause.
Quality and growth
ROE
ROE avg
ROE min
Profit CAGR
Profit YoY
Net profit
EPS up
Loss years (last ~5)
Dividends and safety
Div years
Dividend yield
Payout
Cash div
D/E
Loans/MCap
Size, liquidity and ownership
MCap
Free float
Daily turnover
Sponsor %
Inst. %
Public %
Foreign %
Shareholding
- Sponsor/director 31.6%
- Institution 11.3%
- Foreign 19.6%
- Public 37.5%
Audited history
| Year | EPS (Tk) | NAV/share | Net profit (cr) | Cash div % | Bonus % |
|---|---|---|---|---|---|
| 2021 | 2.52 | 41.19 | 20 | — | — |
| 2022 | 3.42 | 43.41 | 27 | 11 | 0 |
| 2023 | 3.59 | 43.98 | 36 | 13 | 0 |
| 2024 | 3.77 | 42.46 | 40 | 14 | 0 |
| 2025 | 4.54 | 45.29 | 49 | 14 | 0 |
Fiscal year ends June. EPS, NAV and profit are as audited by the company and published by DSE. Financials last fetched: 14/11/2026.
Shariah screen (partial)
Business screen and the debt ratio (loans / market cap 0.9%, limit 33%) are automated. Interest income (under 5% of revenue) and cash/investment ratios must be checked in the annual report.
Educational, not investment advice. Verify on DSE and StockNow before making any decision.